See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Research Videos on Diabetes Health TV

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Christoph Westphal, MD, Ph.D - CEO SIRTRIS (GSK)

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

Medtronic Diabetes

Courtney Parkin

Medtronic Diabetes

Diabetes Medications Research

Page 4
Diabetes Drug Tied to Reduced Breast Cancer Risk
Apr 22, 2010 | 
The study, published in the journal Diabetes Care, adds to evidence that metformin, a generically available drug commonly used for type 2 diabetes, may have anti-cancer effects.
Synthetic Molecule That Stops Diabetic Inflammation Could Become a Type 2 Therapy
Apr 8, 2010 | 
Tests of an experimental drug called CPSI-1306 at Ohio State University were so successful at lowering inflammation and blood sugar levels in lab mice with type 2 diabetes that scientists consider it a prime candidate to become a new therapy for the disease. 
DHTV
Popular
Top Rated

Related Research Videos on Diabetes Health TV

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Christoph Westphal, MD, Ph.D - CEO SIRTRIS (GSK)

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

Medtronic Diabetes

Courtney Parkin

Medtronic Diabetes

Valsartan (Diovan) Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance
Mar 20, 2010 | 
Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan (Diovan) delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.
Mutation That Affects Response to Smell and Taste Could Lead to Type 2 Diabetes
Mar 19, 2010 | 
According to Duke University researchers, a mutation that causes the lack of an insulin-controlling molecule may be a factor in the development of type 2 diabetes. The molecule, ankyrin B, is activated in response to the smell and taste of food and leads to the production of insulin in preparation for food intake.
Dolphins' Ability to Switch Diabetes On and Off Could Point to a Similar Knack in Humans
Mar 13, 2010 | 
A scientist's discovery that dolphins have a genetic ability to turn diabetes on and off, depending on the availability of food, could lead to research into whether humans might have a similar-although dormant-gene.
GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia
Feb 23, 2010 | 
The Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia (rosiglitazone) that are based on analyses that are not consistent with the rigorous scientific evidence supporting the safety of the drug. In addition, the report cherry-picks information from documents, which mischaracterizes GlaxoSmithKline's comprehensive efforts to research Avandia and communicate those findings to regulators, physicians and patients. In fact, the safety and effectiveness of Avandia is well characterized in the label approved by the FDA.
U.S. Senate Report Says Glaxo Knew that Avandia Increases Risk of Heart Attacks
Feb 22, 2010 | 
A U.S. Senate Finance Committee report released on February 20 says that Avandia, GlaxoSmithKline's drug for type 2 diabetes, may have caused as many as 83,000 heart attacks between 1999, when the drug was introduced, and 2007. The Senate report, culminating a two-year inquiry into the drug, also says that Glaxo knew about the drug's potential risks years before suspicions began to form regarding a connection between Avandia and heart problems.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.